Objectives: Health care organizations are under increasing pressure to deliver value by improving test utilization management. Many factors, including organizational factors, could affect utilization performance. Past research has focused on the impact of specific interventions in single organizations. The impact of organizational factors is unknown. The objective of this study is to determine whether testing patterns are subject to organizational effects, ie, are utilization patterns for individual tests correlated within organizations.
Health care organizations are under increasing pressure to deliver value. 1, 2 Value is defined as the ratio of outcomes (health outcomes and patient satisfaction) to cost. Many organizations have initiated programs to improve value by reducing costs and improving outcomes. [2] [3] [4] [5] [6] [7] [8] [9] [10] In laboratory medicine, such programs are typically called laboratory utilization management programs. Laboratory utilization management involves a continuous process of identifying targets (improvement opportunities) and selecting interventions. Targets are identified by two broad approaches: absolute and relative. In the absolute approach, practice is compared with guidelines. Comparison to practice guidelines is the most objective and preferred method. 2, 11 Many examples demonstrating the value of this approach are available in the literature. [12] [13] [14] [15] [16] However, there are relatively few guidelines available to guide appropriate test selection, so the absolute approach is limited. 17 The quality of guidelines is also known to be variable, and the validity of guidelines is dependent on the quality of the data used in their creation. 16, 18, 19 In the relative approach, practice is compared with other organizations. The relative approach identifies practice variation with the underlying hypothesis that differences in practice may represent inappropriate utilization. This is sometimes called benchmarking. 20, 21 Benchmarking is a useful tool for assessing utilization. 22 Organizations must choose relevant metrics for comparisons in benchmarking studies. A variety of external services are available to laboratories for this purpose. test utilization. Such metrics must be normalized to facilitate valid comparisons. Volume-based measures are convenient, but they can be criticized because they describe behavior rather than performance. Other metrics, such as positivity rate, provide a normalized metric that is more closely related to performance. A low positivity rate may be a signal of overutilization: tests are ordered in the context of low clinical suspicion. Similarly, a high positivity rate may suggest underutilization. In this case, the threshold for testing is too high. Thus, the positivity rate may serve as a useful benchmark for test utilization. Research in this area is early but promising. 11, 26 Benchmarking studies are complicated because there are many causes of practice variation. To make valid comparisons, researchers must control or adjust for these factors. Such factors can occur at an organizational level (eg, management policies, organizational culture) or at lower levels of analysis such as individual tests. Organizational factors could affect testing behavior across a range of tests throughout the organization. Traditionally, utilization studies have addressed a limited selection of tests with targeted interventions. 27 Little is known about the impact of organization factors on testing behavior. To date, studies have instead focused on individual patient or doctor factors as determinants of test utilization. 12, 15, [28] [29] [30] Indeed, it is not known whether organizations have significant differences in performance or testing behavior. Geographic variation in utilization of diagnostic testing, therapeutics, and interventions, as well as variation in charges, has been widely documented. [31] [32] [33] [34] [35] [36] [37] [38] This suggests a possible role for organizationlevel factors contributing to variation in health care delivery.
In this study, we examine organizational differences in testing behavior. We compare testing performance of three genetic tests for hereditary thrombophilia. We selected these tests because of the interest in utilization of genetic tests. We compared positivity rates of these genetic tests across a large cohort of organizations. The objective or this study was to provide a proof of concept for an organizational-level metric of test utilization. That is, can we identify organizational levels of variation of test utilization that cannot be explained by variation in individual tests?
Materials and Methods

Data Extraction
We extracted 4 years (January 24, 2011, through January 23, 2015) of de-identified laboratory test result data (n ¼ 202,887) for three common hypercoagulation assays (activated protein C resistance [APCR], factor V Leiden [FVL] mutation, and prothrombin gene mutation [PTGM] ) performed at ARUP Laboratories. We excluded results with incomplete information.
Result Classification
Using regular expression parsing in the Python programming language (Anaconda 3.5.1; Continuum Analytics, Austin, TX), we classified abnormal results using defined criteria: heterozygous or homozygous results for APCR or FVL, less than the defined reference range for APCR. We removed results deemed not classifiable (n ¼ 216), examples of which included "Not Done," "Order Error," and "See Note."
Organization Selection
An organization was defined as any entity that submitted orders to our reference laboratory. An organization may consist of a single facility or multiple facilities, in the case of an integrated health system. For each assay, we only included organizations that had ordered at least 50 tests of the test of interest during the study period. We excluded test results from reference laboratories because they aggregate orders from many organization types. We excluded organization types that had low representation (n < 20). Thus, our sample was limited to community hospitals and academic medical centers.
We counted accessions for each organization and calculated the fraction of abnormal results for each assay by organization. For FVL, we excluded organizations that sent no APCR assays to our reference laboratory during the study period (n ¼ 68) since these organizations were presumed to perform APCR in house first and thus only send a subset of cases to us for confirmation purposes, which could bias the analysis. We confirmed this testing strategy in a subset of cases by contacting the individual organizations directly to confirm our hypothesis.
We excluded FVL test data resulting from a reflex protocol, including a preliminary APCR screen to prevent bias of FVL positivity rates. Our laboratory offers FVL as a part of a reflex test and as an individual test. Our information system enables us to determine whether an FVL order was placed as an individual test or as part of reflex test by the test order code that is used for the order. We included only results from orders for the individual test. We were also aware that clients sometimes perform the screening test (APCR) themselves and, if positive, subsequently order FVL from a reference laboratory. We identified such laboratories by sorting ordering laboratories by FVL positivity rate and, starting with the laboratory with the highest positivity rate, called to inquire about their FVL workflow.
Specifically, we investigated whether the laboratory performed APCR in house and, if FVL was ordered, FVL for positive results by APCR. We excluded laboratories that performed APCR as an in-house screening assay. We continued down the list until we found two laboratories that did not perform APCR. This remaining set of laboratories was included in the analysis. Thus, we used two methods to exclude FVL orders based on positive APCR results: (1) an internal method based on the test order code and (2) an external method based on a survey of contributing organizations.
Calculation of Expected Prevalence
We used ethnicity data to predict the assay positivity rate. We obtained county-level data from the 2010 US Census data. 39 We used county-level ethnicity data for the organization's ZIP code location and published population prevalences for FVL and prothrombin gene mutations to make our predictions. [39] [40] [41] [42] We used published FVL mutation prevalence for both the FVL predictions and the APCR predictions. 41 In cases where the organization ZIP code spanned more than one county (n ¼ 82), we averaged the ethnicity data for involved counties that the organization ZIP code encompassed. We joined these results to other organization-level demographic data, including facility type (academic vs community, etc), inpatient electronic medical record system (vendor), facility size (bed number), and organization patient mix (fraction of Medicare, Medicaid, and private or self-paying patients). Organization characteristics were determined using an external database supplied by Definitive Healthcare (Natick, MA).
Statistical Analysis
Calculations were performed using Stata 14 (StataCorp, College Station, TX). Analysis of heterogeneity of positivity rates was performed using meta-analysis (metaprop command in Stata) and evaluated using a v 2 statistic, Higgins I 2 . The association between predicted and observed prevalence was performed using simple linear regression. We used hierarchical regression to study organization-level factors associated with positivity rates. In this model, we used the predicted positivity rate and order volume as test-level predictors and used bed size, facility type (academic vs community hospital), electronic health record vendor, and patient population (percent Medicare/Medicaid) as fixed organization-level predictors of the observed positivity rate. Organization identification was included as a random effect. The intraclass correlation coefficient was used to assess the organization-level variation in positivity rate.
Results
Characteristics of the Study Cohort
Our study included 169,418 test results from 659 organizations located in 44 different states. Organizations were grouped into two categories Table 1 : academic medical centers (n ¼ 53, 8.0%) and community hospitals (n ¼ 606, 92.0%). The hospital size (number of beds) ranged from 24 to 912 (median, 230; interquartile range, 139-343). Academic hospitals were generally larger than community hospitals (mean difference, 152 beds; t ¼ -6.91, P < .001).
Distribution of Positivity Rates by Organization and by Test
The percent positivity showed considerable variation between organizations Figure 1 . For APCR, the positivity rate ranged from 0% to 22.8%. For PTGM, the positivity rate ranged from 0% to 13.9%. For FVL, the positivity rate ranged from 2.0% to 30.7%. The heterogeneity in positivity rate (ie, variation between organizations) was statistically significant for all three tests Table 2 .
Association of Positivity Rate With Prevalence
All three tests showed a statistically significant association with prevalence Figure 2 and Table 3 . The predicted prevalence explained 12.9%, 2.6%, and 24.4% of the variation in observed prevalence (positivity rate) for APCR, PTGM, and FVL, respectively.
Organization-Level Variation
In a hierarchical model, hospital size (number of beds) had a negative association with the observed positivity rate (coefficient ¼ -0.00004; 95% confidence interval [CI], -0.00006 to -0.00002). The intraclass correlation coefficient for organization was 0.11 (95% CI, 0.04-0.29). The standard deviation of the residuals for organization was 3.0% and was significantly greater than zero (v 2 1 ¼ 3.9, P ¼ .02). The distribution of estimated organization effects is shown in Figure 3 . Facility type, order volume, patient population (percent Medicare/Medicaid), and electronic medical record vendor were not associated with the observed positivity rate.
Discussion
Our results show statistically significant organization-level variation in the positivity rate for three genetic tests for coagulation disorders. We found that results for several tests (observed positivity rate) were correlated among organizations. That is, for a given organization, the positivity rate tends to move in the same direction for all three tests. The entries describe the distribution of positivity rate for each test. The v 2 test for heterogeneity tests whether the variation in positivity rates between organizations is significant relative to the uncertainty in positivity rates. Higgins I 2 estimates the proportion of variation in positivity rates that is due to organization differences rather than uncertainty in the estimate of the positivity rate. There are at least two reasons why test positivity might vary by organization: differences in testing threshold and differences in patient populations. Organizational factors such as management programs, policies, or culture can affect testing behavior. For example, physicians in an organization with an active utilization management program might have a higher threshold for testing than an organization without a utilization program. Such a threshold would be reflected across a wide range of tests.
Differences in positivity rate could also arise from differences in the underlying population. For example, prothrombin and FVL mutations are more common in white patients compared with other ethnic groups. Thus, we may expect that the test positivity rate for these assays would be higher in geographic areas where white patients make up a larger fraction of the total patient population. We controlled for differences in population by calculating the expected prevalence based on the ethnicity composition of the county where each hospital was located. Although this method is imperfect, we found statistically significant associations between the observed and predicted prevalence and were able to at least partially control for the natural variation in prevalence. Population differences could also arise from differences in referral patterns or other mechanisms that preferentially select specific groups of patients.
It is interesting to note that hospital size had a negative association with observed test positivity rate. We hypothesized that larger organizations may be more likely to have a utilization management program in place and thus engage in more judicious use of these tests. Our findings do not support this hypothesis. Instead, it may be that larger organizations are more likely to have house staff placing orders, and these junior providers are less expert in placing appropriate orders. Trainees are known drivers of test utilization. 43 This utilization is variable and education curriculum dependent. 44 Very limited data suggest that senior staff may use laboratory testing more efficiently than junior physicians. 15 This particular topic clearly merits additional study given the role house staff play in care delivery.
Our interest in test positivity arose from an interest in test utilization. We sometimes use the positivity rate of a test as a benchmark with the hypothesis that unusually high or low positivity rates may reflect over-or underutilization of tests. In this study, we investigated whether patterns of test positivity for several different tests are correlated within an organization. We selected three tests that would likely be ordered by the same organizational unit for a single condition (thrombophilia). We are unable to prove that the organization-level differences are due to organizational factors, but barring population differences, the results are suggestive. It would be interesting to supplement the analysis with interviews at organizations at either end of the spectrum and ask about organizational factors that would have a broad impact across tests.
To our knowledge, this is the first analysis of organization-level effects on test ordering patterns. We used hierarchical regression analysis to separate test-level factors from organization-level factors. More broadly, this type of analysis can be used to identify organization-level factors associated with practice variation in testing. The analysis can also provide benchmarking data that can be used to compare organizational-level performance. For example, benchmarking data could be useful to the organizations that have organizationlevel effects that are at the ends of the distribution Figure 3 . Such information could prompt investigations and interventions to change testing patterns. Similarly, this type of benchmarking could be used to provide feedback to physicians on their ordering behavior. In particular, feedback on positivity rates could help doctors interpret tests more accurately as well as direct them toward more targeted test use. As in our analysis, public data could be combined with private data to provide decision support tailored for a specific location.
The objective or our study was to conduct a proof-ofconcept study on the potential value of benchmarking utilization management performance at an organizational level. In a sense, our analysis provides an organizational scorecard for utilization management. We do not provide absolute benchmarks. Rather, our approach is to provide relative organization-level benchmarks based on practice variation. For example, we might designate organizations in the top and bottom 2.5th percentile of Figure 3 as "outliers." These organizations have positivity rates that suggest a systemic organization-wide effect on test utilization.
Investigations of test utilization consume resources and should be used selectively. Our organization-level analysis may help identify organizations that might benefit from a managerial audit of their approach to test utilization. Our analysis is not directed toward test-level comparisons. The objective is to provide organizational benchmarks that give an indication of organizational performance across a range of tests. The analysis identifies variation in organizational performance that cannot be explained by variation in individual tests.
How should an organization that is identified as an outlier proceed? Outlier status is not necessarily a marker of poor performance. It does indicate deviation from a normative medical practice. Accordingly, areas of high variation merit investigation. As we discussed earlier, there are two approaches: an absolute approach based on guidelines and a relative approach based on the distribution of results from similar organizations. Guidelines are the preferred approach. In the absence of guidelines, relative analyses of individual tests such as those shown in Figures 1 and 2 might provide a starting point for investigation of an organization's relative performance (Figure 3 ). Assuming that this type of information can help direct managerial attention toward utilization projects, the next question is, "How can we provide organizations with this type of information?"
Reference laboratories are uniquely suited to assess population-level utilization. Whereas traditional health care organizations pass little information between institutions, reference laboratories collect information from many organizations. This functionality can be expanded with the use of other publicly available data, such as the census data used in our study. We also had hospital-level data (bed size, order volumes) for each organization to use in our models. At the same time, our study is limited because we did not have access to clinical data other than age, sex, and the test results, as additional clinical information is not typically passed to the reference laboratory. Reference laboratory data can be an asset for population health research but could be more effective with better data exchange.
Our work has several limitations. We assumed that the ethnic composition of a hospital's patient population was the same as the county where the hospital is located. This is a strong assumption. It would have been better to use census data from each hospital, but that was not available. We also used a simple hierarchy: testing clustered by organization. We ignored other potential sources of clustering such as physicians, departments, and hospital networks. This could be an area of future research. We tested several potential organizational predictors, but none of these accounted for the organization-level variation. Thus, despite investigation of several potential predictors, there is probably at least one unidentified variable that predicts organizational performance. For example, we did not have information on local-level management practices that would have enriched the analysis. Identifying these variables could be a target for future research.
Practice variation is a significant concern across health care. Historically, research has documented the extent of practice variation but not explained the reasons for variation. Our analysis shows an approach that can be used to explain variation by examining factors at each level of a hierarchy. This line of research could be extended to more granularly define the contribution of organization-level factors related to genetic testing such as those described in this article or to assess drivers of utilization in other assay categories.
Conclusion
Organizations have a statistically significant impact on the positivity rate of three genetic tests. 
